HOME >> MEDICINE >> NEWS
HbA1 Predicts Coronary Artery Disease In Female But Not Male Type 1 Diabetics, Says University Of Pittsburgh Researcher

A University of Pittsburgh research team has found that HbA1 (hemoglobin A1) predicts mortality or death from coronary artery disease (CAD) in women with Type 1 diabetes but not in men with this disease. HbA1 is a known indicator of prolonged high blood sugar. These results are being presented at the 39th annual conference on Cardiovascular Disease Epidemiology and Prevention, March 25, in Orlando, Fla.

"This gender-specific role of hyperglycemia may explain the lack of usual male excess of coronary artery disease death rates in diabetes," said Trevor Orchard, M.D., principal investigator, professor of medicine and pediatrics in the University of Pittsburgh School of Medicine, and professor of epidemiology in the Graduate School of Public Health.

To assess the role diabetes control might play in the development or progression of CAD, the team analyzed eight-year incidence data from the Pittsburgh Epidemiology of Diabetes Complication Study. This is a 10-year prospective study of 658 subjects whose insulin-dependent diabetes was diagnosed in childhood. The average age of participants at the beginning of the study was 27.6 years, and their diabetes had been diagnosed for 19.4 of those years. Dr. Orchard said that CAD developed in 77 patients, 25 of whom died.


'"/>

Contact: Franki Williams
williamsf@msx.upmc.edu
412-624-2607
University of Pittsburgh Medical Center
26-Mar-1999


Page: 1

Related medicine news :

1. More Cystic Fibrosis Patients Will Die Waiting For Lung Transplants, Predicts University Of Pittsburgh Study
2. Ultrasonography Predicts Heart Attack/Stroke Risk
3. ESC releases the first European Guidelines on Percutaneous Coronary Interventions (PCI)
4. Coronary stents do not improve long-term survival
5. Coronary aneurysms are independent predictor of mortality, should be aggressively monitored
6. Coronary heart disease risk assessment improves with coronary artery calcium scoring
7. Coronary artery calcium can be a warning sign of fatal cardiac event
8. American Heart Association Comment: Contributions Of Trends In Survival And Coronary-Event Rates To Changes In Coronary Heart Disease Mortality
9. Routine Use Of Coronary Stents Found To Yield Better Outcomes, Be More Cost-Effective
10. National Clinical Trial To Test Effectiveness Of Antibiotic Treatment For Coronary Artery Disease
11. Artery clearing system does not provide benefit for patients undergoing PCI

Post Your Comments:
(Date:5/21/2013)... Today, Zane Benefits, Inc. published a ... accounts. Zane Benefits, which provides comprehensive and flexible alternatives ... in defined contribution and http://HRA ... to Zane Benefits’ website, the Affordable Care Act (known ... in 2010 and impacts many areas of health care ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Two executives ... Guidance (SBG) will identify which strategies can be most ... high-quality care to the members who are taking them, ... Services, Inc., “How to Manage Specialty Drugs to ... pharmaceuticals are now the main driver for rising prescription ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 While North ... synonymous with comprehensive travel guides. Brunswick Plantation & Golf ... packages that include access to 27 holes of "Top10" ... courses in North Carolina, knowing the Top 10 ... Lodges takes away the overwhelming task of selecting the ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Octo ... technology and management consulting solutions to the Federal ... Business Development. In the newly created role, ... all aspects of the firm’s business development function ... proposal management functions, and leading strategies to achieve ...
(Date:5/21/2013)... HealthDay Reporter , , TUESDAY, May 21 (HealthDay News) ... therapy for patients having severe bouts of chronic obstructive ... days of glucocorticoid treatment with prednisone to treat COPD ... but with fewer chances for adverse side effects, they ... period of treatment was not less effective than 14 ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 3Health News:Consulting Firm Execs to Discuss Strategies for Effective Management of Specialty Drugs in AIS’s May 30 Webinar 2Health News:Brunswick Plantation & Golf Resort Named in Top 10 Golf Resorts in North Carolina 2Health News:Octo Consulting Group Appoints Tracy Denny as Vice President of Business Development 2Health News:COPD Patients May Do Fine With Shorter Course of Steroids 2Health News:COPD Patients May Do Fine With Shorter Course of Steroids 3
(Date:5/21/2013)... and TARRYTOWN, N.Y. , May 21, ... and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that ... online the positive Phase 2a study results of dupilumab ... an investigational monoclonal antibody targeting the alpha subunit of ... of both IL-4 and IL-13, drivers of Th2 (Type ...
(Date:5/21/2013)... Calif. , May 21, 2013 Abaxis, ... blood analysis systems, announced today that Martin ... at the Stifel Annual Dental & Veterinary Conference on ... conference will be held at Le Parker Meridien Hotel ... About Abaxis Abaxis develops, manufactures, markets ...
(Date:5/21/2013)... 2013 Reportlinker.com announces that a ... its catalogue:   ... Medical Devices in the US Market ... Changing Regulatory and Reimbursement Scenario for ...   Summary ...
Breaking Medicine Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4
Cached News: